Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) has continued to collect additional input on its i/Blue Imaging System from physicians in the United States and Canada.
Leading urologists observing simulated cystoscopy demonstrations noted that the systems’ simultaneous viewing of white and blue light images during bladder cancer resection has the potential to improve surgical technique.
“Since beginning our market research at the American Urology’s Association meeting last May, we have received valuable positive feedback,” Jim Hutchens, president and CEO of Imagin, said in a statement.
“We look forward to continuing our conversations with urologists at this year’s AUA meeting as we move closer to delivering the i/Blue’s benefits to the medical community,” he added.
